Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Accumulated Expenses (2016 - 2023)

Historic Accumulated Expenses for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $1.5 million.

  • Aptevo Therapeutics' Accumulated Expenses rose 1115.16% to $1.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.5 million, marking a year-over-year increase of 1115.16%. This contributed to the annual value of $2.1 million for FY2022, which is 134.81% up from last year.
  • According to the latest figures from Q3 2023, Aptevo Therapeutics' Accumulated Expenses is $1.5 million, which was up 1115.16% from $1.3 million recorded in Q2 2023.
  • In the past 5 years, Aptevo Therapeutics' Accumulated Expenses registered a high of $5.0 million during Q1 2019, and its lowest value of $627000.0 during Q1 2023.
  • For the 5-year period, Aptevo Therapeutics' Accumulated Expenses averaged around $1.9 million, with its median value being $1.6 million (2021).
  • Per our database at Business Quant, Aptevo Therapeutics' Accumulated Expenses skyrocketed by 13494.87% in 2019 and then plummeted by 7848.08% in 2020.
  • Aptevo Therapeutics' Accumulated Expenses (Quarter) stood at $2.9 million in 2019, then decreased by 3.94% to $2.8 million in 2020, then dropped by 24.66% to $2.1 million in 2021, then rose by 1.35% to $2.1 million in 2022, then decreased by 27.55% to $1.5 million in 2023.
  • Its last three reported values are $1.5 million in Q3 2023, $1.3 million for Q2 2023, and $627000.0 during Q1 2023.